CSF3 and neutropenia: The results remained consistent with those observed in the overall population: in patients treated with “7 + 3”, G-CSF significantly reduced the duration of neutropenia (median 19 vs. 22 days, p < 0.001), hospitalization (median 36 vs. 41 days, p = 0.034), and ABT (median 15 vs. 20.5 days, p = 0.032).